- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04622241
Uganda Housing Modification Study (UHMS)
Impact of Housing Modifications Combined With Piperonyl Butoxide (PBO) Long-lasting Insecticidal Nets (LLINs) on the Malaria Burden in Uganda: a Cluster-randomised Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
The study will be conducted in two phases, beginning with a pilot (Phase I). The aim of the pilot will be to develop and test four types of housing modifications in both modern houses (those with brick or stone walls) and traditionally constructed houses (those with mud walls). The housing modifications will include: (1) full house screening (eaves and windows), (2) partial house screening (eaves or ceiling), (3) eave tubes, and (4) eave ribbons. Community input will be sought during the development of the housing prototypes.
In the pilot, all 4 interventions will be implemented in both modern and traditional houses, plus a control arm in each group. All households will have access to PBO LLINs. Community input will be sought during the development of the housing prototypes. The pilot will include 10 arms in total, each consisting of 20 households, equal to 200 households (160 in the intervention and 40 in the control arm) in total. The feasibility and effectiveness of the interventions will be assessed through a qualitative study (FGDs and interviews), evaluation of the costs and implementation of the interventions, and entomology surveys (using CDC light traps). One to two housing interventions will be selected for Phase II following the review and discussion of the pilot results with the trial steering committee.
Phase II will include a cluster-randomised trial. A cluster will be defined as a village (or segment of a village consisting of ~100 households). In the cluster-randomised trial, up to 2 interventions vs 1 control arm will be assessed in 20 clusters per arm (60 clusters total). The clusters will be non-contiguous, with a buffer zone of 300-500m. All households in the selected clusters will have PBO LLINs; households in intervention clusters will also receive the specified housing modifications. The impact of the interventions will be assessed through a cohort study, cross-sectional community surveys, entomology surveillance, a qualitative study, and an economic evaluation. The primary outcome of the trial will be clinical malaria incidence in children aged < 60 months as measured in the cohort study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Central Region
-
Kampala, Central Region, Uganda
- Infectious Diseases Research Collaboration
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Phase I
Inclusion criteria
- At least one adult aged 18 years or older present
- Agreement of the adult resident to provide informed consent for the pilot study
Phase II
Cohort Study
Inclusion Criteria:
- Household considered their primary residence
- Child aged less than 59 months
- Agreement to come to the study clinic for any febrile illness
- Agreement to avoid antimalarial medications outside the study
- Provision of written informed consent (for parent or guardian in case of children)
Cross-sectional Community Survey - Household Survey
Inclusion Criteria:
- At least one household resident between 6 months and 14 years of age present (with an adult caregiver willing to provide informed consent for the clinical survey)
- At least one adult aged 18 years or older present
- Adult is a usual resident who slept in the sampled household on the night before the survey
- Agreement of the adult resident to provide informed consent for the household survey
Exclusion Criteria:
- Dwelling destroyed or not found
- Household vacant
- No adult resident home on more than 3 occasions
Cross-sectional Community Survey - Clinical Survey
Inclusion Criteria:
- Child aged 6 months to 14 years
- Usual resident who was present in the sampled household on the night before the survey
- Agreement of parent/guardian to provide informed consent
- Agreement of child aged 8 years or older to provide assent
Exclusion Criterion:
- Child not home on day of survey
Recruitment of Field Workers for entomology activities (human landing catches).
Inclusion Criteria:
- Willingness to take chemoprophylaxis for malaria
- Willingness to abstain from alcohol during working hours
- No significant past medical history.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Eave Tubes - Traditional House
Installation of eave tubes in traditional homes.
|
The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g.
bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides.
No additional screening will be done.
All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
|
|
Experimental: Eave Tubes - Modern House
Installation of eave tubes in modern homes.
|
The eave tubes are PVC tubes with a diameter of 15 cm installed in the outer wall of occupied rooms (e.g.
bedrooms and living rooms but not storage rooms) at 1.5-2 m intervals, fitted with electrostatic mesh inserts coated with insecticides.
No additional screening will be done.
All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
|
|
Experimental: Eave Ribbons - Traditional House
Installation of eave ribbons in traditional homes.
|
Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial). All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents. |
|
Experimental: Eave Ribbons - Modern House
Installation of eave ribbons in modern homes.
|
Eave ribbons are 15 cm-wide triple-layered hessian fabrics (burlap-line fabric woven from sisal fibres, procured locally), in lengths starting 1 m that can be attached to houses using nails, adhesives or Velcro, without completely closing eave-spaces. The eave ribbons will be treated by study staff with a commonly used spatial repellent, transfluthrin. Eave ribbons will be retreated by study staff after 6 months (only in Phase II, if selected for inclusion in the cluster-randomised trial). All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents. |
|
Experimental: Full House Screening - Traditional House
Installation of full house screening, includes screening eaves and windows, in traditional homes.
|
Full house screening includes screening eaves/ceilings, ventilation openings, and windows.
Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials.
or ceilings, if eaves are closed" and ventilation openings.
We are also filling in any gaps in the walls.
All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
|
|
Experimental: Full House Screening - Modern House
Installation of full house screening, includes screening eaves and windows, in modern homes.
|
Full house screening includes screening eaves/ceilings, ventilation openings, and windows.
Eaves/ceiling, air vents, and windows of eligible houses will be screened with wire mesh or other locally available screening materials.
or ceilings, if eaves are closed" and ventilation openings.
We are also filling in any gaps in the walls.
All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
|
|
Experimental: Partial House Screening - Traditional House
Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in traditional homes.
|
Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present.
In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls.
No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
|
|
Experimental: Partial House Screening - Modern House
Installation of partial screening, includee either screening of the eaves or installing a screened ceiling, in modern homes.
|
Partial screening will include either screening of the eaves or installing a screened ceiling, where no ceiling is present.
In traditional houses, a netting (either insecticide-impregnated or untreated) may be either fixed in multiple places in the rafters or by hanging from a single central point and attached to the walls.
No other screening or filling of the gaps will be done in partially screened houses.All households will be provided with piperonyl butoxide (PBO) long-lasting insecticidal nets (LLINs) - one for every two residents.
|
|
No Intervention: Control - Traditional House
Control group with no intervention in traditional homes
|
|
|
No Intervention: Control - Modern House
Control group with no intervention in modern homes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of malaria
Time Frame: 12 months following housing modification
|
Number of incident episodes of clinical malaria per time of observation.
Incident episodes of malaria defined as any treatment for malaria > 14 days after any prior treatment for malaria
|
12 months following housing modification
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Parasite prevalence
Time Frame: 12 months following housing modification
|
Proportion of study participants with a thick blood smear positive for asexual parasites as measured by microscopy
|
12 months following housing modification
|
|
Prevalence of anaemia
Time Frame: 12 months following housing modification
|
Proportion of haemoglobin measurements categorised as anaemia as per WHO age-stratified guidelines
|
12 months following housing modification
|
|
Vector density
Time Frame: 12 months following housing modification
|
Number of female Anopheles mosquitoes captured/room per night by CDC light traps
|
12 months following housing modification
|
|
Sporozoite rate
Time Frame: 12 months following housing modification
|
Proportion of captured female Anopheles mosquitoes that test positive for sporozoites
|
12 months following housing modification
|
|
Annual entomological inoculation rate
Time Frame: 12 months following housing modification
|
Number of infected bites per person per year (human biting rate x sporozoite rate x 365 days/year)
|
12 months following housing modification
|
|
Proportion of mosquitoes with insecticide resistance
Time Frame: 12 months following housing modification
|
Proportion of mosquitoes with phenotypic expression of insecticide resistance or containing genetic polymorphisms associated with resistance to insecticides of interest as identified by PCR
|
12 months following housing modification
|
|
Proportion of individuals satisfied with the interventions
Time Frame: 12 months following housing modification
|
Indicator of acceptability
|
12 months following housing modification
|
|
Proportion of households that require minimal maintenance of the implemented intervention over the period of the study, by study intervention
Time Frame: 12 months following housing modification
|
Indicator of durability
|
12 months following housing modification
|
|
Longer term cost of the maintenance and upkeep of the implemented intervention, by study intervention
Time Frame: 12 months following housing modification
|
Indicator of durability
|
12 months following housing modification
|
|
Costs of housing improvements, including maintenance, by improvement type
Time Frame: 12 months following housing modification
|
Indicator of feasibility
|
12 months following housing modification
|
|
Incremental cost-effectiveness ratios (ICER) of each package
Time Frame: 12 months following housing modification
|
Cost per malaria case averted, Cost per DALY averted
|
12 months following housing modification
|
|
Proportion of households that received the assigned housing modification
Time Frame: 12 months following housing modification
|
Indicator of fidelity
|
12 months following housing modification
|
|
Proportion of households that received 1 PBO LLIN for every 2 residents
Time Frame: 12 months following housing modification
|
Indicator of fidelity
|
12 months following housing modification
|
|
Proportion of households that received full/partial/no housing modifications
Time Frame: 12 months following housing modification
|
Dose delivered
|
12 months following housing modification
|
|
Proportion of households that received adequate/inadequate/no PBO LLINs
Time Frame: 12 months following housing modification
|
Dose delivered
|
12 months following housing modification
|
|
Proportion of households that utilized full/partial/no housing modifications
Time Frame: 12 months following housing modification
|
Dose received
|
12 months following housing modification
|
|
Proportion of household residents that slept under a PBO LLIN the previous night
Time Frame: 12 months following housing modification
|
Dose received
|
12 months following housing modification
|
|
Proportion of households that were fully covered by the assigned housing modification
Time Frame: 12 months following housing modification
|
Indicator of reach
|
12 months following housing modification
|
|
Proportion of household residents that were fully covered by the PBO LLINs
Time Frame: 12 months following housing modification
|
Indicator of reach Proportion of households fully covered by both the modifications & PBO LLINs |
12 months following housing modification
|
|
Proportion of households fully covered by both the modifications & PBO LLINs
Time Frame: 12 months following housing modification
|
Indicator of reach
|
12 months following housing modification
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nelli Westercamp, PhD MBA, Centers for Disease Control and Prevention
- Principal Investigator: Moses Kamya, MBChB PhD, Infectious Diseases Research Collaboration
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 72061720FA00002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
ESI-PGIMSR, BasaidarapurCompletedAnemia | Iron Deficiency Anemia of Pregnancy | Iron Deficiency Anemia Treatment | Anemia, Postpartum | FCMIndia
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Italy, Spain, United Kingdom, Hungary
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)Netherlands, Germany, Italy, United Kingdom, United States, France
-
China Immunotech (Beijing) Biotechnology Co., Ltd.Not yet recruitingAutoimmune Hemolytic AnemiaChina
-
Peking Union Medical College HospitalNot yet recruiting
-
Institute of Hematology & Blood Diseases Hospital...Not yet recruitingSevere Aplastic Anemia | Refractory Aplastic Anemia | Newly Diagnosed Aplastic Anemia
-
Chinese PLA General HospitalBeijing Friendship Hospital; Beijing 302 Hospital; The University of Hong Kong-Shenzhen... and other collaboratorsEnrolling by invitationSevere Aplastic Anemia | Severe Aplastic Anemia (SAA) | Severe Aplastic Anemia, RefractoryChina
-
Children's Hospital Medical Center, CincinnatiRecruiting
Clinical Trials on Eave Tubes
-
The University of Texas Health Science Center,...Completed
-
Aljazeera HospitalNot yet recruiting
-
Centre Hospitalier Universitaire de NiceBio-Rad LaboratoriesCompletedSepsisFrance, Monaco
-
David Chi, MDActive, not recruitingRecurrent Acute Otitis Media | Chronic Otitis Media With Effusion | Otitis Media in ChildrenUnited States
-
Eunice Kennedy Shriver National Institute of Child...CompletedOtitis Media | Middle Ear EffusionUnited States
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Institute of Child HealthNational Institute for Health Research, United Kingdom; Great Ormond Street...CompletedGastrostomy | Stem Cell Transplant Complications | Enteral Feeding Intolerance | Bone Marrow Disease | Gastrostomy Complications | Experiences, LifeUnited Kingdom
-
OtoSonics Inc.UnknownOtitis Media With Effusion | Middle Ear Effusion
-
Institut Paoli-CalmettesINSERM-U1068Active, not recruitingMalignant HemopathyFrance
-
University Hospital, GrenobleInstitute for Advanced Biosciences (IAB), GrenobleNot yet recruitingInflammatory Bowel Disease (IBD)France